BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16331266)

  • 1. A peptide aptamer to antagonize BCL-6 function.
    Chattopadhyay A; Tate SA; Beswick RW; Wagner SD; Ko Ferrigno P
    Oncogene; 2006 Apr; 25(15):2223-33. PubMed ID: 16331266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
    Huynh KD; Bardwell VJ
    Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
    Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
    Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCoR, a novel corepressor involved in BCL-6 repression.
    Huynh KD; Fischle W; Verdin E; Bardwell VJ
    Genes Dev; 2000 Jul; 14(14):1810-23. PubMed ID: 10898795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
    Zacharchenko T; Kalverda AP; Wright SC
    Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene.
    Vasanwala FH; Kusam S; Toney LM; Dent AL
    J Immunol; 2002 Aug; 169(4):1922-9. PubMed ID: 12165517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
    Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional repression by the proto-oncogene BCL-6.
    Seyfert VL; Allman D; He Y; Staudt LM
    Oncogene; 1996 Jun; 12(11):2331-42. PubMed ID: 8649773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.
    Dhordain P; Lin RJ; Quief S; Lantoine D; Kerckaert JP; Evans RM; Albagli O
    Nucleic Acids Res; 1998 Oct; 26(20):4645-51. PubMed ID: 9753732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of fish BCL-6 and Blimp-1 in vitro: transcriptional repressors for B-cell terminal differentiation in fugu (Takifugu rubripes).
    Ohtani M; Miyadai T
    Mol Immunol; 2011 Mar; 48(6-7):818-25. PubMed ID: 21216469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
    Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
    Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
    Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
    Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.
    Wong CW; Privalsky ML
    J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
    Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
    Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
    Chang CC; Ye BH; Chaganti RS; Dalla-Favera R
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):6947-52. PubMed ID: 8692924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
    Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
    Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.
    Onizuka T; Moriyama M; Yamochi T; Kuroda T; Kazama A; Kanazawa N; Sato K; Kato T; Ota H; Mori S
    Blood; 1995 Jul; 86(1):28-37. PubMed ID: 7795234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.
    Phan RT; Dalla-Favera R
    Nature; 2004 Dec; 432(7017):635-9. PubMed ID: 15577913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mad1 is a transcriptional repressor of Bcl-6.
    Lee SC; Bottaro A; Chen L; Insel RA
    Mol Immunol; 2006 May; 43(12):1965-71. PubMed ID: 16423395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6.
    Reljic R; Wagner SD; Peakman LJ; Fearon DT
    J Exp Med; 2000 Dec; 192(12):1841-8. PubMed ID: 11120780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.